Effects of new diabetes drugs on diabetic kidney disease are mixed

SAN DIEGO – At a joint session of the American Society of Nephrology and the ADA as part of the ADA's 77th Scientific Sessions, nephrologists presented data on how diabetes drugs in the SGLT2, GLP-1 receptor agonists and DPP-4 inhibitors classes affected diabetes patients with diabetic kidney disease.